Section
This study found that patient-reported speech/voice and related head-and-neck symptoms can help predict hypoglossal neuropathy risk after oropharyngeal cancer treatment, supporting earlier surveillance with the MDASI-HN-NERVE score.
MSI-H/dMMR gastroesophageal adenocarcinoma showed high response rates to immune checkpoint inhibitors, including durable complete responses in locoregional disease that may support carefully selected nonoperative management.
This single-center cohort found high and durable checkpoint inhibitor responses in dMMR/MSI-H gastroesophageal adenocarcinoma, including complete responses in locoregional disease that may support carefully selected nonoperative management.
In a large TriNetX study, GLP-1 receptor agonists were associated with better overall survival and lower locoregional recurrence than bariatric surgery alone in obese postmenopausal women with stage 0-III breast cancer.
A matched-cohort study found that multimodal prehabilitation during neoadjuvant chemotherapy improved chemotherapy delivery and increased the chance of interval debulking surgery in advanced ovarian cancer, with the strongest benefits seen
Single-cell profiling of colorectal cancer lymph nodes revealed an SPP1–CD44–NF-κB1 pathway that promotes CD137+ regulatory T-cell maturation and may be therapeutically targetable.
A Danish registry study found no overall increase in selected cancers after gestational diabetes, but did observe a small absolute and relative increase in kidney cancer risk.
TROPHAMET found that first-line avelumab plus methotrexate achieved 96.2% hCG normalization in low-risk gestational trophoblastic tumors with manageable toxicity, no relapses at 41 months, and preserved fertility.
This case report details successful management of RET-altered medullary thyroid carcinoma using tarlatamab after selpercatinib progression, highlighting modified dosing to mitigate toxicities and achieve complete response.
In two US cohorts, combining serum cancer biomarkers and Histoplasma antibodies with the Mayo model improved discrimination of benign versus malignant pulmonary nodules, especially in intermediate-risk cases.
A mixed-methods study suggests pelvic exenteration offers meaningful long-term survival in selected patients with recurrent cervical cancer, while qualitative data reveal persistent physical, social, and sexual burdens that standardized qua
A 64-year-old man with RET-altered medullary thyroid carcinoma who progressed on selpercatinib achieved complete response after modified dosing of tarlatamab with manageable CRS/ICANS.
Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in advanced hormone receptor-positive, ERBB2-negative breast cancer, with manageable safety and no clear quality-of-life loss.
Population-based testing for breast cancer pathogenic variants identified many women who would not have been flagged by clinical or polygenic risk models, supporting its role in risk-based screening.
A large study of veterans with cancer found persistent risk of suicidal self-directed violence, especially in younger, unmarried, frail, or mentally ill patients and those with central nervous system, head and neck, or thyroid cancers.
A phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.
Long-term follow-up from the DOREMY phase 2 trial shows that reduced-dose preoperative radiotherapy for localized myxoid liposarcoma achieved excellent local control with relatively low toxicity.
A long-term phase 2 trial found that reduced-dose preoperative radiotherapy followed by surgery provided excellent local control and acceptable toxicity in localized myxoid liposarcoma.
A Medicare-based study found the Oncology Care Model did not increase systemic therapy starts for newly diagnosed cancer and was linked to less treatment initiation and lower spending in poor-prognosis cancer.
This WISDOM Study analysis found that most women with breast cancer pathogenic variants would not have been flagged for high-risk screening by clinical or polygenic risk models alone, supporting population-based genetic testing.
